

PROVINCIAL FUNDING SUMMARY

Nivolumab (Opdivo) in combo with Ipilimumab (Yervoy) for Renal Cell Carcinoma (pCODR 10132)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: November 16, 2018

This information is current as of August 1, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	May 1, 2019	First line treatment for intermediate or poor-risk advanced renal-cell carcinoma <ul style="list-style-type: none"> • Any histology • Good performance status • Adequate hepatic and renal function • Access to a treatment centre with expertise to manage immune-mediated adverse reactions of checkpoint inhibitors • A BC Cancer “Compassionate Access Program” approval prior to treatment
AB	Funded	Jul 16, 2019	Nivolumab plus ipilimumab in patients with intermediate or poor risk advanced renal cell carcinoma (RCC) based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. Eligible patients should have RCC previously untreated in the metastatic setting and have a good performance status. Treatment should continue until disease progression. At the time of listing patients who previously started on first line targeted agents who have not experienced disease progression may move to this therapy.
SK	Funded	Jun 1, 2019	Combination use of Nivolumab plus Ipilimumab followed by Nivolumab maintenance for previously untreated patients with intermediate or poor-risk advanced renal cell carcinoma based on International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
MB	Funded	Jun 5, 2019	For the first line treatment of patients with: <ul style="list-style-type: none"> • Advanced or metastatic renal cell carcinoma (RCC) AND • Intermediate or poor risk disease (according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) AND • A good performance status.
ON	Funded	May 15, 2019	Combination nivolumab plus ipilimumab is used for the treatment of previously untreated patients with intermediate or poor-risk advanced renal cell carcinoma based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria.
NS	Funded	Jul 1, 2019	As combination use of nivolumab plus ipilimumab for the treatment of patients with IMDC intermediate or poor-risk advanced or metastatic renal cell carcinoma based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. Eligible patients should be previously untreated in the metastatic setting and have a good performance status (KPS \geq 70). Treatment should continue until disease progression or unacceptable toxicity.
NB	Funded	Jun 28, 2019	For the treatment of patients with intermediate or poor risk advanced or metastatic renal cell carcinoma based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. Patients must be previously untreated in the metastatic setting and have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.
NL	Funded	Jul 16, 2019	Combination of Ipilimumab and Nivolumab, followed by Nivolumab maintenance for previously untreated patients with intermediate or poor-risk advanced renal cell carcinoma [based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria] of any histology. Patients must have good performance status (ECOG 0-2).
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations.

Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.